No_老虎社区_美港股上老虎

Zlatan
2021-12-24

U.S. authorizes Merck pill as second at-home COVID-19 treatment

Dec 23 (Reuters) - The U.S. on Thursday authorized Merck & Co's(MRK.N)antiviral pill for COVID-19 fo

U.S. authorizes Merck pill as second at-home COVID-19 treatment

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

推荐
最新

暂无评论

热议股票

关于我们·老虎社区守则·老虎社区账号管理规范·老虎社区服务协议·老虎社区隐私政策

公司名称：北京至简风宜信息技术有限公司

违法和不良信息投诉：010-5681-3562（工作时间9:30-18:30）

邮箱：service@laohu8.com

营业执照：91110105MA01A4U55R

ICP备：京ICP备18016422号

网安备：京公网安备11010502036490

关注我们

{"i18n":{"language":"zh_CN"},"data":{"magic":2,"id":698395449,"tweetId":"698395449","gmtCreate":1640301773093,"gmtModify":1640301774476,"author":{"id":3586734124712023,"idStr":"3586734124712023","authorId":3586734124712023,"authorIdStr":"3586734124712023","name":"Zlatan","avatar":"https://static.tigerbbs.com/851e5397e61566365d8aa47e422075b4","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":5,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":31,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body>No</body></html>","htmlText":"<html><head></head><body>No</body></html>","text":"No","highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/698395449","repostId":1154370846,"repostType":4,"repost":{"id":"1154370846","kind":"news","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1640299823,"share":"https://www.laohu8.com/m/news/1154370846?lang=&edition=full","pubTime":"2021-12-24 06:50","market":"us","language":"en","title":"U.S. authorizes Merck pill as second at-home COVID-19 treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=1154370846","media":"Reuters","summary":"Dec 23 (Reuters) - The U.S. on Thursday authorized Merck & Co's(MRK.N)antiviral pill for COVID-19 fo","content":"Dec 23 (Reuters) - The U.S. on Thursday authorized Merck &amp; Co's(MRK.N)antiviral pill for COVID-19 for certain high-risk adult patients, a day after giving a broader go-ahead to a&nbsp;similar but more effective treatment&nbsp;from Pfizer Inc.\nThe U.S. Food and Drug Administration said Merck's drug could be used when other authorized treatments are not accessible or clinically appropriate.\nThe drug,molnupiravir, was developed with Ridgeback Biotherapeutics and shown to reduce hospitalizations and deaths by around 30% in a clinical trial of high-risk individuals early in the course of the illness.\nThe authorization allows use of the drug for mild-to-moderate COVID-19 and along with the&nbsp;Pfizer pill, could be an important tool against the fast-spreading Omicron variant, which is now dominant in the United States.\nPfizer's drug,Paxlovid, was authorized on Wednesday for people aged 12 and older and has shown to be nearly 90% effective in preventing hospitalizations and deaths in patients at high risk of severe illness, according to trial data.\nThe FDA says some patients should avoid Pfizer's two-drug regimen because it includes an older antiviral called ritonavir that is known to have interactions with some other prescription medicines. It is also not recommended for people with severe kidney issues.\nMerck plans to ship hundreds of thousands of treatment courses in coming days and 1 million over the next few weeks. Pfizer plans to ship about 250,000 courses in the next month.\nAvailability of other treatments is the first consideration for doctors thinking of prescribing Merck's treatment, according to Patrizia Cavazzoni, the director of FDA's Center for Drug Evaluation and Research.\nThe FDA has authorized intravenous treatments, mostly for hospital use, called monoclonal antibodies but availability is limited and efficacy against the Omicron variant is lower.\nFDA official John Farley said during a press briefing that GlaxoSmithKline's&nbsp;and Vir Biotech's&nbsp;antibody drug - which has been shown to work against Omicron - is expected to be in short supply this winter.\nMerck said that its treatment had advantages over the Pfizer pill.\n\"It doesn't require any second drug to boost its efficacy, and you can give it in a variety of special patient populations, including people who have significant issues with liver function or kidney function,\" Nick Kartsonis, Merck's senior vice president of clinical research for vaccines and infectious diseases, told Reuters.\n\"This approval comes at the right time since more COVID-19 treatments are needed to supplement the vaccination effort, especially in light of variants of concern,\" said Cantor Fitzgerald analyst Louise Chen.\nNearly 62% of people in the United States are fully vaccinated, leaving many Americans unprotected against a wave of Omicron infections. Two doses of the highly successful vaccine from Pfizer Inc and BioNTech SE are only somewhat protective against infection with the Omicron variant while a third dose improves the immune response.\nMerck's and Pfizer's antiviral both work by preventing the virus from replicating. Merck's pill does so by introducing errors into the genetic code of the virus.\nSome of the FDA's experts have said that could lead to more troublesome variants.\nThere have also been some safety concerns around the drug because it may affect bone cartilage and growth.\nDue to that reason, Merck's drug is not authorized for use in patients younger than 18, the FDA said. The pill is not recommended for use during pregnancy, the agency added.\nThe agency advised that men of reproductive potential use a reliable method of birth control during treatment with molnupiravir, and for at least three months after the final dose.\nThe drug is meant to be taken twice a day - four pills each time - for five days, making a full treatment course 40 pills. The treatment was priced at about $700 per course in a deal with the U.S. government for up to 5 million courses.\nThe U.S. government has ordered 10 million courses of the Pfizer drug at a price of $530 per course compares to the deal with Merck for as many as 5 million courses of molnupiravir at a price of $700 per course.\nMerck has said molnupiravir, which helps prevent the virus from replicating, should be effective against any variant, including the new Omicron variant.","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>U.S. authorizes Merck pill as second at-home COVID-19 treatment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nU.S. authorizes Merck pill as second at-home COVID-19 treatment\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\nReuters \n2021-12-24 06:50\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\nDec 23 (Reuters) - The U.S. on Thursday authorized Merck &amp; Co's(MRK.N)antiviral pill for COVID-19 for certain high-risk adult patients, a day after giving a broader go-ahead to a&nbsp;similar but more effective treatment&nbsp;from Pfizer Inc.\nThe U.S. Food and Drug Administration said Merck's drug could be used when other authorized treatments are not accessible or clinically appropriate.\nThe drug,molnupiravir, was developed with Ridgeback Biotherapeutics and shown to reduce hospitalizations and deaths by around 30% in a clinical trial of high-risk individuals early in the course of the illness.\nThe authorization allows use of the drug for mild-to-moderate COVID-19 and along with the&nbsp;Pfizer pill, could be an important tool against the fast-spreading Omicron variant, which is now dominant in the United States.\nPfizer's drug,Paxlovid, was authorized on Wednesday for people aged 12 and older and has shown to be nearly 90% effective in preventing hospitalizations and deaths in patients at high risk of severe illness, according to trial data.\nThe FDA says some patients should avoid Pfizer's two-drug regimen because it includes an older antiviral called ritonavir that is known to have interactions with some other prescription medicines. It is also not recommended for people with severe kidney issues.\nMerck plans to ship hundreds of thousands of treatment courses in coming days and 1 million over the next few weeks. Pfizer plans to ship about 250,000 courses in the next month.\nAvailability of other treatments is the first consideration for doctors thinking of prescribing Merck's treatment, according to Patrizia Cavazzoni, the director of FDA's Center for Drug Evaluation and Research.\nThe FDA has authorized intravenous treatments, mostly for hospital use, called monoclonal antibodies but availability is limited and efficacy against the Omicron variant is lower.\nFDA official John Farley said during a press briefing that GlaxoSmithKline's&nbsp;and Vir Biotech's&nbsp;antibody drug - which has been shown to work against Omicron - is expected to be in short supply this winter.\nMerck said that its treatment had advantages over the Pfizer pill.\n\"It doesn't require any second drug to boost its efficacy, and you can give it in a variety of special patient populations, including people who have significant issues with liver function or kidney function,\" Nick Kartsonis, Merck's senior vice president of clinical research for vaccines and infectious diseases, told Reuters.\n\"This approval comes at the right time since more COVID-19 treatments are needed to supplement the vaccination effort, especially in light of variants of concern,\" said Cantor Fitzgerald analyst Louise Chen.\nNearly 62% of people in the United States are fully vaccinated, leaving many Americans unprotected against a wave of Omicron infections. Two doses of the highly successful vaccine from Pfizer Inc and BioNTech SE are only somewhat protective against infection with the Omicron variant while a third dose improves the immune response.\nMerck's and Pfizer's antiviral both work by preventing the virus from replicating. Merck's pill does so by introducing errors into the genetic code of the virus.\nSome of the FDA's experts have said that could lead to more troublesome variants.\nThere have also been some safety concerns around the drug because it may affect bone cartilage and growth.\nDue to that reason, Merck's drug is not authorized for use in patients younger than 18, the FDA said. The pill is not recommended for use during pregnancy, the agency added.\nThe agency advised that men of reproductive potential use a reliable method of birth control during treatment with molnupiravir, and for at least three months after the final dose.\nThe drug is meant to be taken twice a day - four pills each time - for five days, making a full treatment course 40 pills. The treatment was priced at about $700 per course in a deal with the U.S. government for up to 5 million courses.\nThe U.S. government has ordered 10 million courses of the Pfizer drug at a price of $530 per course compares to the deal with Merck for as many as 5 million courses of molnupiravir at a price of $700 per course.\nMerck has said molnupiravir, which helps prevent the virus from replicating, should be effective against any variant, including the new Omicron variant.\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRK":"默沙东"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1154370846","content_text":"Dec 23 (Reuters) - The U.S. on Thursday authorized Merck & Co's(MRK.N)antiviral pill for COVID-19 for certain high-risk adult patients, a day after giving a broader go-ahead to a similar but more effective treatment from Pfizer Inc.\nThe U.S. Food and Drug Administration said Merck's drug could be used when other authorized treatments are not accessible or clinically appropriate.\nThe drug,molnupiravir, was developed with Ridgeback Biotherapeutics and shown to reduce hospitalizations and deaths by around 30% in a clinical trial of high-risk individuals early in the course of the illness.\nThe authorization allows use of the drug for mild-to-moderate COVID-19 and along with the Pfizer pill, could be an important tool against the fast-spreading Omicron variant, which is now dominant in the United States.\nPfizer's drug,Paxlovid, was authorized on Wednesday for people aged 12 and older and has shown to be nearly 90% effective in preventing hospitalizations and deaths in patients at high risk of severe illness, according to trial data.\nThe FDA says some patients should avoid Pfizer's two-drug regimen because it includes an older antiviral called ritonavir that is known to have interactions with some other prescription medicines. It is also not recommended for people with severe kidney issues.\nMerck plans to ship hundreds of thousands of treatment courses in coming days and 1 million over the next few weeks. Pfizer plans to ship about 250,000 courses in the next month.\nAvailability of other treatments is the first consideration for doctors thinking of prescribing Merck's treatment, according to Patrizia Cavazzoni, the director of FDA's Center for Drug Evaluation and Research.\nThe FDA has authorized intravenous treatments, mostly for hospital use, called monoclonal antibodies but availability is limited and efficacy against the Omicron variant is lower.\nFDA official John Farley said during a press briefing that GlaxoSmithKline's and Vir Biotech's antibody drug - which has been shown to work against Omicron - is expected to be in short supply this winter.\nMerck said that its treatment had advantages over the Pfizer pill.\n\"It doesn't require any second drug to boost its efficacy, and you can give it in a variety of special patient populations, including people who have significant issues with liver function or kidney function,\" Nick Kartsonis, Merck's senior vice president of clinical research for vaccines and infectious diseases, told Reuters.\n\"This approval comes at the right time since more COVID-19 treatments are needed to supplement the vaccination effort, especially in light of variants of concern,\" said Cantor Fitzgerald analyst Louise Chen.\nNearly 62% of people in the United States are fully vaccinated, leaving many Americans unprotected against a wave of Omicron infections. Two doses of the highly successful vaccine from Pfizer Inc and BioNTech SE are only somewhat protective against infection with the Omicron variant while a third dose improves the immune response.\nMerck's and Pfizer's antiviral both work by preventing the virus from replicating. Merck's pill does so by introducing errors into the genetic code of the virus.\nSome of the FDA's experts have said that could lead to more troublesome variants.\nThere have also been some safety concerns around the drug because it may affect bone cartilage and growth.\nDue to that reason, Merck's drug is not authorized for use in patients younger than 18, the FDA said. The pill is not recommended for use during pregnancy, the agency added.\nThe agency advised that men of reproductive potential use a reliable method of birth control during treatment with molnupiravir, and for at least three months after the final dose.\nThe drug is meant to be taken twice a day - four pills each time - for five days, making a full treatment course 40 pills. The treatment was priced at about $700 per course in a deal with the U.S. government for up to 5 million courses.\nThe U.S. government has ordered 10 million courses of the Pfizer drug at a price of $530 per course compares to the deal with Merck for as many as 5 million courses of molnupiravir at a price of $700 per course.\nMerck has said molnupiravir, which helps prevent the virus from replicating, should be effective against any variant, including the new Omicron variant.","news_type":1},"isVote":1,"tweetType":1,"viewCount":799,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":2,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"hasMoreComment":false,"orderType":2}